Review of the proposed generic drug and biosimilars user fees and further examination of drug shortages : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, February 9, 2012.

Similar Items

• Review of the proposed generic drug and biosimilars user fees and further examination of drug shortages : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, February 9, 2012.
  Published: (2013)
• Hearing on the Review of the Proposed Generic Drug and Biosimilars User Fees and Further Examination of Drug Shortages
  Published: (2012)
• Hearing on "Examining FDA's Generic Drug and Biosimilar User Fee Programs."
  Published: (2017)
• Hearing Entitled "Examining FDA's Generic Drug and Biosimilar User Fee Programs"
  Published: (2017)
• Generic Drug Applications : FDA Should Take Additional Steps To Address Factors That May Affect Approval Rates in the First Review Cycle.
  Published: (2019)